VitalStone Financial’s CRISPR Therapeutics CRSP Stock Holding History

VitalStone Financial’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.03K	Hold	22	–	–	﹤0.01%	420
2024 Q2	$1.19K	Sell	22 -10	-31%	-$578	﹤0.01%	414
2024 Q1	$2K	Sell	32 -70	-69%	-$5.01K	﹤0.01%	395
2023 Q4	$6K	Hold	102	–	–	﹤0.01%	323
2023 Q3	$5K	Sell	102 -27	-21%	-$1.39K	﹤0.01%	304
2023 Q2	$5K	Sell	129 -63	-33%	-$3.58K	﹤0.01%	715
2023 Q1	$15K	Buy	192 +67	+54%	+$3.25K	0.01%	182
2022 Q4	$4K	Buy	+125	New	+$6.63K	﹤0.01%	415

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VitalStone Financial's CRSP Position: Q3 2024 in Review

VitalStone Financial held its CRISPR Therapeutics (CRSP) position steady in Q3 2024 at 22 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #420.

VitalStone Financial first reported a position in CRSP in Q4 2022 and has held it in 8 quarters since. The position peaked at $15K in Q1 2023. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

VitalStone Financial held 22 shares of CRISPR Therapeutics worth $1.03K as of Q3 2024.
VitalStone Financial left its CRISPR Therapeutics share count unchanged in Q3 2024.
CRISPR Therapeutics made up ﹤0.01% of VitalStone Financial's portfolio in Q3 2024, its #420 holding.
VitalStone Financial first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 8 quarters since.
VitalStone Financial's CRISPR Therapeutics position peaked at $15K in Q1 2023.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on VitalStone Financial's 13F filing for Q3 2024, filed 11 Oct 2024.